<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00928668</url>
  </required_header>
  <id_info>
    <org_study_id>1222.4</org_study_id>
    <nct_id>NCT00928668</nct_id>
  </id_info>
  <brief_title>Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent Asthma</brief_title>
  <official_title>Randomised, Double-Blind, Placebo-Controlled, 5-Way Cross-Over Study to Assess the Efficacy (Bronchoprotection) and Safety of a Single Dose of Orally Inhaled BI 1744 CL (2, 5, 10 and 20ug) in Patients With Intermittent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the efficacy (bronchoprotection) and safety
      of single doses of BI 1744 CL inhalation solution (2, 5, 10 and 20 mcg) delivered via the
      Respimat® inhaler, in patients with intermittent asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adjusted Mean of Provocative Concentration of Methacholine Required to Produce a 20% Decrease in FEV1 (PC20FEV1) at 24 Hours</measure>
    <time_frame>24 hours post dose</time_frame>
    <description>Provocative concentration of methacholine required to produce a 20% decrease in FEV1 (PC20FEV1) at 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean of Provocative Concentration of Methacholine Required to Produce a 20% Decrease in FEV1 (PC20FEV1) at 30 Minutes</measure>
    <time_frame>30 minutes post dose</time_frame>
    <description>Provocative concentration of methacholine required to produce a 20% decrease in FEV1 (PC20FEV1) at 30 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean of Provocative Concentration of Methacholine Required to Produce a 20% Decrease in FEV1 (PC20FEV1) at 4 Hours</measure>
    <time_frame>4 hours post dose</time_frame>
    <description>Provocative concentration of methacholine required to produce a 20% decrease in FEV1 (PC20FEV1) at 4 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean of Provocative Concentration of Methacholine Required to Produce a 20% Decrease in FEV1 (PC20FEV1) at 8 Hours</measure>
    <time_frame>8 hours post dose</time_frame>
    <description>Provocative concentration of methacholine required to produce a 20% decrease in FEV1 (PC20FEV1) at 8 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean of Provocative Concentration of Methacholine Required to Produce a 20% Decrease in FEV1 (PC20FEV1) at 32 Hours</measure>
    <time_frame>32 hours post dose</time_frame>
    <description>Provocative concentration of methacholine required to produce a 20% decrease in FEV1 (PC20FEV1) at 32 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG</measure>
    <time_frame>5 days</time_frame>
    <description>Clinical relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG. New abnormal findings or worsenings of baseline conditions were reported as Adverse Events (cardiac disorders and investigations).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Testing: Average Change From Baseline of Potassium and Calcium</measure>
    <time_frame>Baseline to Visit 6</time_frame>
    <description>Laboratory testing: Average change from baseline of potassium and calcium measured on test-days</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Olodaterol (BI1744) Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dosing of low dose Olodaterol inhaled orally from Respimat Device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olodaterol (BI1744) Medium Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dosing of medium low dose Olodaterol inhaled orally from Respimat Device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olodaterol (BI1744) Medium High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dosing of medium high dose Olodaterol inhaled orally from Respimat Device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olodaterol (BI 1744) High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dosing of high dose Olodaterol inhaled orally from Respimat Device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dosing of Olodaterol placebo inhaled orally from Respimat Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo device for comparison</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol (BI1744CL)</intervention_name>
    <description>Olodaterol comparison of low, medium low, medium high and high doses</description>
    <arm_group_label>Olodaterol (BI1744) Medium High</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol (BI1744CL)</intervention_name>
    <description>Olodaterol comparison of low, medium low, medium high and high doses</description>
    <arm_group_label>Olodaterol (BI1744) Low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol (BI1744CL)</intervention_name>
    <description>Olodaterol comparison of low, medium low, medium high and high doses</description>
    <arm_group_label>Olodaterol (BI1744) Medium Low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol (BI1744CL)</intervention_name>
    <description>Olodaterol comparison of low, medium low, medium high and high doses</description>
    <arm_group_label>Olodaterol (BI 1744) High</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Diagnosis of intermittent asthma according to Global Initiative for Asthma criteria

          2. Non-smokers or ex-smokers who have not smoked for at least 1 year and have a smoking
             history of less than 5 pack-years

          3. Forced Expiratory Volume in 1second greater than or equal to 80% predicted normal
             (Visit 1).

          4. Bronchial hyperresponsiveness to inhaled methacholine with a provocative concentration
             of a methacholine causing a 20% fall in Forced Expiratory Volume in one second less
             than or equal to 8 mg/mL (Visit 1).

          5. Be able to perform technically acceptable pulmonary function tests

          6. Be able to inhale medication in a competent manner from the Respimat® inhaler

          7. Must sign and date an informed consent consistent with International Conference on
             Harmonisation-Good Clinical Practice guidelines prior to participation in the trial,
             which includes medication washout and restrictions.

        Exclusion criteria

          1. Patients with a significant disease other than asthma

          2. Patients with seasonal asthma or allergies whose participation in the trial will occur
             during the season for which they are allergic.

          3. Patients with clinically relevant abnormal baseline haematology, blood chemistry, or
             urinalysis; all patients with a serum glutamic oxaloacetic transaminase &gt; 80 IU/L,
             serum glutamic pyruvic transaminase &gt; 80 IU/L, bilirubin &gt;2.0 mg/dL or creatinine &gt;
             2.0 mg/dL will be excluded regardless of clinical condition

          4. Patients with any of the following conditions: a diagnosis of hyperthyrosis or
             paroxysmal tachycardia (&gt;100 beats per minute), a marked baseline prolongation of
             QT/QTc interval, a history of additional risk factors for Torsade de Pointes, a
             history of myocardial infarction, a diagnosis of clinically relevant cardiac
             arrhythmia, a history of cor pulmonale, known active tuberculosis, a malignancy for
             which the patient has undergone resection, radiation therapy or chemotherapy within
             the last five years (patients with treated basal cell carcinoma are allowed), a
             history of life-threatening pulmonary obstruction, a history of cystic fibrosis,
             clinically evident bronchiectasis, or a history of significant alcohol or drug abuse.

          5. Patients who have undergone thoracotomy with pulmonary resection

          6. Patients who are being treated with any of the following concomitant medications:
             medications that prolong the QT/QTc interval, oral beta-adrenergics, beta-blockers or
             monoamine oxidase inhibitors or tricyclic antidepressants.

          7. Patients who have been treated with any respiratory medications (excluding
             short-acting beta-agonists) for control of their asthma symptoms within 3 months of
             the Screening Visit (Visit 1).

          8. Patients who have taken an investigational drug within one month or six half lives
             (whichever is greater) prior to Screening Visit (Visit 1).

          9. Pregnant or nursing women, or women of childbearing potential not using a highly
             effective method of birth control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1222.4.103 UBC - Respiratory Medicine</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.4.104 Department of Medicine, Health Sciences Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.4.101 2725 Chemin Ste Foy</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.4.102</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2009</study_first_submitted>
  <study_first_submitted_qc>June 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2009</study_first_posted>
  <results_first_submitted>March 28, 2014</results_first_submitted>
  <results_first_submitted_qc>May 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 1, 2014</results_first_posted>
  <last_update_submitted>May 29, 2014</last_update_submitted>
  <last_update_submitted_qc>May 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a randomised, double-blind, placebo-controlled, 5-way crossover trial. The duration of each treatment period was 1 day with a 14 day washout period between treatments.</recruitment_details>
      <pre_assignment_details>One patient was randomized, but the trial was put on hold so that the patient had to be discontinued and re-randomized. This causes a discrepancy between the 32 patients enrolled and the 31 patients reported for the participant flow.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Olo 5mcg / Olo 2mcg / Olo 10mcg / Placebo / Olo 20mcg</title>
          <description>Patients were administered Olodaterol 5 mcg qd in the first period, Olodaterol 2 mcg qd in the second period, Olodaterol 10 mcg qd in the third period, matching Placebo in the fourth period and Olodaterol 20 mcg qd in the fifth period. Olodaterol was administered via the Respimat inhaler.</description>
        </group>
        <group group_id="P2">
          <title>Olo 10mcg / Olo 20mcg / Olo 2mcg / Olo 5mcg / Placebo</title>
          <description>Patients were administered Olodaterol 10 mcg qd in the first period, Olodaterol 20 mcg qd in the second period, Olodaterol 2 mcg qd in the third period, Olodaterol 5 mcg qd in the fourth period and matching Placebo in the fifth period. Olodaterol was administered via the Respimat inhaler.</description>
        </group>
        <group group_id="P3">
          <title>Olo 2mcg / Placebo / Olo 20mcg / Olo 10mcg / Olo 5mcg</title>
          <description>Patients were administered Olodaterol 2 mcg qd in the first period, matching Placebo in the second period, Olodaterol 20 mcg qd in the third period, Olodaterol 10 mcg qd in the fourth period and Olodaterol 5 mcg qd in the fifth period. Olodaterol was administered via the Respimat inhaler.</description>
        </group>
        <group group_id="P4">
          <title>Olo 20mcg / Olo 5mcg / Placebo / Olo 2mcg / Olo 10mcg</title>
          <description>Patients were administered Olodaterol 20 mcg qd in the first period, Olodaterol 5 mcg qd in the second period, matching Placebo in the third period, Olodaterol 2 mcg qd in the fourth period and Olodaterol 10 mcg qd in the fifth period. Olodaterol was administered via the Respimat inhaler.</description>
        </group>
        <group group_id="P5">
          <title>Placebo / Olo 10mcg / Olo 5mcg / Olo 20mcg / Olo 2mcg</title>
          <description>Patients were administered matching Placebo in the first period, Olodaterol 10 mcg qd in the second period, Olodaterol 5 mcg qd in the third period, Olodaterol 20 mcg qd in the fourth period and Olodaterol 2 mcg qd in the fifth period. Olodaterol was administered via the Respimat inhaler.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons not listed above</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Total</title>
          <description>Total number of patients treated in the study. This was a randomised, double-blind, placebo-controlled, 5-way crossover trial. 31 patients were assigned randomly to one of 5 treatment sequences in which they received each of 5 treatments. The duration of each treatment period was 1 day with a 14 day washout period between treatments.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.9" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Mean of Provocative Concentration of Methacholine Required to Produce a 20% Decrease in FEV1 (PC20FEV1) at 24 Hours</title>
        <description>Provocative concentration of methacholine required to produce a 20% decrease in FEV1 (PC20FEV1) at 24 hours</description>
        <time_frame>24 hours post dose</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and post-dose data for at least two periods for the same endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol (Olo) 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olodaterol (Olo) 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olodaterol (Olo) 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olodaterol (Olo) 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean of Provocative Concentration of Methacholine Required to Produce a 20% Decrease in FEV1 (PC20FEV1) at 24 Hours</title>
          <description>Provocative concentration of methacholine required to produce a 20% decrease in FEV1 (PC20FEV1) at 24 hours</description>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and post-dose data for at least two periods for the same endpoint.</population>
          <units>Log base 2 (mg/ml)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.793" spread="0.182"/>
                    <measurement group_id="O2" value="1.950" spread="0.186"/>
                    <measurement group_id="O3" value="2.504" spread="0.190"/>
                    <measurement group_id="O4" value="3.236" spread="0.179"/>
                    <measurement group_id="O5" value="3.777" spread="0.183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using an analysis of variance with terms for centre, patients within centre, treatment and period (all as fixed effects)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.157</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.252</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.657</ci_lower_limit>
            <ci_upper_limit>1.657</ci_upper_limit>
            <estimate_desc>Olo 2 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using an analysis of variance with terms for centre, patients within centre, treatment and period (all as fixed effects)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.711</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.255</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.205</ci_lower_limit>
            <ci_upper_limit>2.217</ci_upper_limit>
            <estimate_desc>Olo 5 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using an analysis of variance with terms for centre, patients within centre, treatment and period (all as fixed effects)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.443</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.248</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.952</ci_lower_limit>
            <ci_upper_limit>2.935</ci_upper_limit>
            <estimate_desc>Olo 10 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using an analysis of variance with terms for centre, patients within centre, treatment and period (all as fixed effects)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.984</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.251</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.486</ci_lower_limit>
            <ci_upper_limit>3.483</ci_upper_limit>
            <estimate_desc>Form 20 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean of Provocative Concentration of Methacholine Required to Produce a 20% Decrease in FEV1 (PC20FEV1) at 30 Minutes</title>
        <description>Provocative concentration of methacholine required to produce a 20% decrease in FEV1 (PC20FEV1) at 30 minutes</description>
        <time_frame>30 minutes post dose</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and post-dose data for at least two periods for the same endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol (Olo) 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olodaterol (Olo) 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olodaterol (Olo) 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olodaterol (Olo) 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean of Provocative Concentration of Methacholine Required to Produce a 20% Decrease in FEV1 (PC20FEV1) at 30 Minutes</title>
          <description>Provocative concentration of methacholine required to produce a 20% decrease in FEV1 (PC20FEV1) at 30 minutes</description>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and post-dose data for at least two periods for the same endpoint.</population>
          <units>Log base 2 (mg/ml)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.393" spread="0.180"/>
                    <measurement group_id="O2" value="2.532" spread="0.184"/>
                    <measurement group_id="O3" value="3.029" spread="0.187"/>
                    <measurement group_id="O4" value="3.953" spread="0.177"/>
                    <measurement group_id="O5" value="4.617" spread="0.181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using an analysis of variance with terms for centre, patients within centre, treatment and period (all as fixed effects)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.139</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.249</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.645</ci_lower_limit>
            <ci_upper_limit>2.633</ci_upper_limit>
            <estimate_desc>Olo 2 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using an analysis of variance with terms for centre, patients within centre, treatment and period (all as fixed effects)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.636</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.252</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.135</ci_lower_limit>
            <ci_upper_limit>3.136</ci_upper_limit>
            <estimate_desc>Olo 5 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using an analysis of variance with terms for centre, patients within centre, treatment and period (all as fixed effects)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.560</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.245</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.074</ci_lower_limit>
            <ci_upper_limit>4.046</ci_upper_limit>
            <estimate_desc>Olo 10 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using an analysis of variance with terms for centre, patients within centre, treatment and period (all as fixed effects)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.224</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.249</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.731</ci_lower_limit>
            <ci_upper_limit>4.717</ci_upper_limit>
            <estimate_desc>Form 20 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean of Provocative Concentration of Methacholine Required to Produce a 20% Decrease in FEV1 (PC20FEV1) at 4 Hours</title>
        <description>Provocative concentration of methacholine required to produce a 20% decrease in FEV1 (PC20FEV1) at 4 hours</description>
        <time_frame>4 hours post dose</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and post-dose data for at least two periods for the same endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol (Olo) 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olodaterol (Olo) 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olodaterol (Olo) 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olodaterol (Olo) 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean of Provocative Concentration of Methacholine Required to Produce a 20% Decrease in FEV1 (PC20FEV1) at 4 Hours</title>
          <description>Provocative concentration of methacholine required to produce a 20% decrease in FEV1 (PC20FEV1) at 4 hours</description>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and post-dose data for at least two periods for the same endpoint.</population>
          <units>Log base 2 (mg/ml)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.577" spread="0.214"/>
                    <measurement group_id="O2" value="2.602" spread="0.219"/>
                    <measurement group_id="O3" value="2.957" spread="0.223"/>
                    <measurement group_id="O4" value="4.126" spread="0.211"/>
                    <measurement group_id="O5" value="4.786" spread="0.215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using an analysis of variance with terms for centre, patients within centre, treatment and period (all as fixed effects)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.025</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.296</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.437</ci_lower_limit>
            <ci_upper_limit>2.613</ci_upper_limit>
            <estimate_desc>Olo 2 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using an analysis of variance with terms for centre, patients within centre, treatment and period (all as fixed effects)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.380</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.300</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.785</ci_lower_limit>
            <ci_upper_limit>2.975</ci_upper_limit>
            <estimate_desc>Olo 5 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using an analysis of variance with terms for centre, patients within centre, treatment and period (all as fixed effects)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.549</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.292</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.971</ci_lower_limit>
            <ci_upper_limit>4.127</ci_upper_limit>
            <estimate_desc>Olo 10 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using an analysis of variance with terms for centre, patients within centre, treatment and period (all as fixed effects)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.208</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.296</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.622</ci_lower_limit>
            <ci_upper_limit>4.794</ci_upper_limit>
            <estimate_desc>Form 20 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean of Provocative Concentration of Methacholine Required to Produce a 20% Decrease in FEV1 (PC20FEV1) at 8 Hours</title>
        <description>Provocative concentration of methacholine required to produce a 20% decrease in FEV1 (PC20FEV1) at 8 hours</description>
        <time_frame>8 hours post dose</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and post-dose data for at least two periods for the same endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol (Olo) 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olodaterol (Olo) 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olodaterol (Olo) 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olodaterol (Olo) 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean of Provocative Concentration of Methacholine Required to Produce a 20% Decrease in FEV1 (PC20FEV1) at 8 Hours</title>
          <description>Provocative concentration of methacholine required to produce a 20% decrease in FEV1 (PC20FEV1) at 8 hours</description>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and post-dose data for at least two periods for the same endpoint.</population>
          <units>Log base 2 (mg/ml)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.576" spread="0.213"/>
                    <measurement group_id="O2" value="2.484" spread="0.218"/>
                    <measurement group_id="O3" value="3.050" spread="0.222"/>
                    <measurement group_id="O4" value="3.903" spread="0.210"/>
                    <measurement group_id="O5" value="4.796" spread="0.214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using an analysis of variance with terms for centre, patients within centre, treatment and period (all as fixed effects)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.907</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.295</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.322</ci_lower_limit>
            <ci_upper_limit>2.492</ci_upper_limit>
            <estimate_desc>Olo 2 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using an analysis of variance with terms for centre, patients within centre, treatment and period (all as fixed effects)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.474</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.299</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.822</ci_lower_limit>
            <ci_upper_limit>3.066</ci_upper_limit>
            <estimate_desc>Olo 5 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using an analysis of variance with terms for centre, patients within centre, treatment and period (all as fixed effects)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.327</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.290</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.752</ci_lower_limit>
            <ci_upper_limit>3.902</ci_upper_limit>
            <estimate_desc>Olo 10 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using an analysis of variance with terms for centre, patients within centre, treatment and period (all as fixed effects)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.220</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.294</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.637</ci_lower_limit>
            <ci_upper_limit>4.803</ci_upper_limit>
            <estimate_desc>Form 20 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean of Provocative Concentration of Methacholine Required to Produce a 20% Decrease in FEV1 (PC20FEV1) at 32 Hours</title>
        <description>Provocative concentration of methacholine required to produce a 20% decrease in FEV1 (PC20FEV1) at 32 hours</description>
        <time_frame>32 hours post dose</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and post-dose data for at least two periods for the same endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol (Olo) 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olodaterol (Olo) 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olodaterol (Olo) 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olodaterol (Olo) 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean of Provocative Concentration of Methacholine Required to Produce a 20% Decrease in FEV1 (PC20FEV1) at 32 Hours</title>
          <description>Provocative concentration of methacholine required to produce a 20% decrease in FEV1 (PC20FEV1) at 32 hours</description>
          <population>Full analysis set (FAS). FAS is defined as all patients that were randomised, received treatment and had baseline data and post-dose data for at least two periods for the same endpoint.</population>
          <units>Log base 2 (mg/ml)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.960" spread="0.200"/>
                    <measurement group_id="O2" value="2.189" spread="0.200"/>
                    <measurement group_id="O3" value="2.785" spread="0.203"/>
                    <measurement group_id="O4" value="3.074" spread="0.192"/>
                    <measurement group_id="O5" value="3.605" spread="0.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using an analysis of variance with terms for centre, patients within centre, treatment and period (all as fixed effects)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.229</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.271</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.692</ci_lower_limit>
            <ci_upper_limit>1.766</ci_upper_limit>
            <estimate_desc>Olo 2 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using an analysis of variance with terms for centre, patients within centre, treatment and period (all as fixed effects)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.825</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.274</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.281</ci_lower_limit>
            <ci_upper_limit>2.369</ci_upper_limit>
            <estimate_desc>Olo 5 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using an analysis of variance with terms for centre, patients within centre, treatment and period (all as fixed effects)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.114</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.270</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.578</ci_lower_limit>
            <ci_upper_limit>2.650</ci_upper_limit>
            <estimate_desc>Olo 10 mcg minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using an analysis of variance with terms for centre, patients within centre, treatment and period (all as fixed effects)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.645</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.270</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.110</ci_lower_limit>
            <ci_upper_limit>3.181</ci_upper_limit>
            <estimate_desc>Form 20 mcg minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG</title>
        <description>Clinical relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG. New abnormal findings or worsenings of baseline conditions were reported as Adverse Events (cardiac disorders and investigations).</description>
        <time_frame>5 days</time_frame>
        <population>The safety set included all patients who received any study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat resp. Aerolizer Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg</title>
            <description>Olodaterol 20 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG</title>
          <description>Clinical relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG. New abnormal findings or worsenings of baseline conditions were reported as Adverse Events (cardiac disorders and investigations).</description>
          <population>The safety set included all patients who received any study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cardiac disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Testing: Average Change From Baseline of Potassium and Calcium</title>
        <description>Laboratory testing: Average change from baseline of potassium and calcium measured on test-days</description>
        <time_frame>Baseline to Visit 6</time_frame>
        <population>All patients in the Safety set who have a baseline value and post dose values for each planned time.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol (Olo) 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olodaterol (Olo) 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olodaterol (Olo) 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olodaterol (Olo) 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Testing: Average Change From Baseline of Potassium and Calcium</title>
          <description>Laboratory testing: Average change from baseline of potassium and calcium measured on test-days</description>
          <population>All patients in the Safety set who have a baseline value and post dose values for each planned time.</population>
          <units>mmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Potassium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit="0.98" upper_limit="1.05"/>
                    <measurement group_id="O2" value="1.04" lower_limit="1.00" upper_limit="1.06"/>
                    <measurement group_id="O3" value="1.02" lower_limit="1.00" upper_limit="1.05"/>
                    <measurement group_id="O4" value="1.00" lower_limit="0.98" upper_limit="1.03"/>
                    <measurement group_id="O5" value="0.98" lower_limit="0.95" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.98" upper_limit="1.03"/>
                    <measurement group_id="O2" value="1.01" lower_limit="0.99" upper_limit="1.02"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.98" upper_limit="1.03"/>
                    <measurement group_id="O4" value="1.00" lower_limit="0.99" upper_limit="1.02"/>
                    <measurement group_id="O5" value="1.01" lower_limit="0.99" upper_limit="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <desc>Single dose including washout phase</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matching Placebo delivered by the Respimat resp. Aerolizer Inhaler.</description>
        </group>
        <group group_id="E2">
          <title>Olo 2 mcg</title>
          <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E3">
          <title>Olo 5 mcg</title>
          <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E4">
          <title>Olo 10 mcg</title>
          <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E5">
          <title>Olo 20 mcg</title>
          <description>Olodaterol 20 mcg qd delivered by the Respimat Inhaler.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

